Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, OS Therapies is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Romness played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OS Therapies
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS). OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years.

To learn more about OS Therapies, visit http://www.ostherapies.com/

Contact:
Paul Romness, Chief Executive Officer
410-297-7793
https://www.linkedin.com/in/paul-romness-97a83886/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved